Defining active progressive multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Defining active progressive multiple sclerosis. / Sellebjerg, Finn; Börnsen, Lars; Ammitzbøll, Cecilie; Nielsen, Jørgen Erik; Vinther-Jensen, Tua; Hjermind, Lena Elisabeth; von Essen, Marina; Ratzer, Rikke Lenhard; Soelberg Sørensen, Per; Romme Christensen, Jeppe.

I: Multiple Sclerosis, Bind 23, Nr. 13, 2017, s. 1727-1735.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sellebjerg, F, Börnsen, L, Ammitzbøll, C, Nielsen, JE, Vinther-Jensen, T, Hjermind, LE, von Essen, M, Ratzer, RL, Soelberg Sørensen, P & Romme Christensen, J 2017, 'Defining active progressive multiple sclerosis', Multiple Sclerosis, bind 23, nr. 13, s. 1727-1735. https://doi.org/10.1177/1352458517726592

APA

Sellebjerg, F., Börnsen, L., Ammitzbøll, C., Nielsen, J. E., Vinther-Jensen, T., Hjermind, L. E., von Essen, M., Ratzer, R. L., Soelberg Sørensen, P., & Romme Christensen, J. (2017). Defining active progressive multiple sclerosis. Multiple Sclerosis, 23(13), 1727-1735. https://doi.org/10.1177/1352458517726592

Vancouver

Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE o.a. Defining active progressive multiple sclerosis. Multiple Sclerosis. 2017;23(13):1727-1735. https://doi.org/10.1177/1352458517726592

Author

Sellebjerg, Finn ; Börnsen, Lars ; Ammitzbøll, Cecilie ; Nielsen, Jørgen Erik ; Vinther-Jensen, Tua ; Hjermind, Lena Elisabeth ; von Essen, Marina ; Ratzer, Rikke Lenhard ; Soelberg Sørensen, Per ; Romme Christensen, Jeppe. / Defining active progressive multiple sclerosis. I: Multiple Sclerosis. 2017 ; Bind 23, Nr. 13. s. 1727-1735.

Bibtex

@article{bc7d56b803404fecb5a2a8ae482d8602,
title = "Defining active progressive multiple sclerosis",
abstract = "BACKGROUND: It is unknown whether disease activity according to consensus criteria (magnetic resonance imaging activity or clinical relapses) associate with cerebrospinal fluid (CSF) changes in progressive multiple sclerosis (MS).OBJECTIVE: To compare CSF biomarkers in active and inactive progressive MS according to consensus criteria.METHODS: Neurofilament light chain (NFL), myelin basic protein (MBP), IgG-index, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), chemokine CXCL13, terminal complement complex, leukocyte counts and nitric oxide metabolites were measured in primary ( n = 26) and secondary progressive MS ( n = 26) and healthy controls ( n = 24).RESULTS: Progressive MS patients had higher CSF cell counts, IgG-index, CHI3L1, MMP-9, CXCL13, NFL and MBP concentrations. Active patients were younger and had higher NFL, CXCL13 and MMP-9 concentrations than inactive patients. Patients with active disease according to consensus criteria or detectable CXCL13 or MMP-9 in CSF were defined as having combined active progressive MS. These patients had increased CSF cell counts, IgG-index and MBP, NFL and CHI3L1 concentrations. Combined inactive patients only had increased IgG-index and MBP concentrations.CONCLUSION: Patients with combined active progressive MS show evidence of inflammation, demyelination and neuronal/axonal damage, whereas the remaining patients mainly show evidence of active demyelination. This challenges the idea that neurodegeneration independent of inflammation is crucial in disease progression.",
author = "Finn Sellebjerg and Lars B{\"o}rnsen and Cecilie Ammitzb{\o}ll and Nielsen, {J{\o}rgen Erik} and Tua Vinther-Jensen and Hjermind, {Lena Elisabeth} and {von Essen}, Marina and Ratzer, {Rikke Lenhard} and {Soelberg S{\o}rensen}, Per and {Romme Christensen}, Jeppe",
year = "2017",
doi = "10.1177/1352458517726592",
language = "English",
volume = "23",
pages = "1727--1735",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "13",

}

RIS

TY - JOUR

T1 - Defining active progressive multiple sclerosis

AU - Sellebjerg, Finn

AU - Börnsen, Lars

AU - Ammitzbøll, Cecilie

AU - Nielsen, Jørgen Erik

AU - Vinther-Jensen, Tua

AU - Hjermind, Lena Elisabeth

AU - von Essen, Marina

AU - Ratzer, Rikke Lenhard

AU - Soelberg Sørensen, Per

AU - Romme Christensen, Jeppe

PY - 2017

Y1 - 2017

N2 - BACKGROUND: It is unknown whether disease activity according to consensus criteria (magnetic resonance imaging activity or clinical relapses) associate with cerebrospinal fluid (CSF) changes in progressive multiple sclerosis (MS).OBJECTIVE: To compare CSF biomarkers in active and inactive progressive MS according to consensus criteria.METHODS: Neurofilament light chain (NFL), myelin basic protein (MBP), IgG-index, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), chemokine CXCL13, terminal complement complex, leukocyte counts and nitric oxide metabolites were measured in primary ( n = 26) and secondary progressive MS ( n = 26) and healthy controls ( n = 24).RESULTS: Progressive MS patients had higher CSF cell counts, IgG-index, CHI3L1, MMP-9, CXCL13, NFL and MBP concentrations. Active patients were younger and had higher NFL, CXCL13 and MMP-9 concentrations than inactive patients. Patients with active disease according to consensus criteria or detectable CXCL13 or MMP-9 in CSF were defined as having combined active progressive MS. These patients had increased CSF cell counts, IgG-index and MBP, NFL and CHI3L1 concentrations. Combined inactive patients only had increased IgG-index and MBP concentrations.CONCLUSION: Patients with combined active progressive MS show evidence of inflammation, demyelination and neuronal/axonal damage, whereas the remaining patients mainly show evidence of active demyelination. This challenges the idea that neurodegeneration independent of inflammation is crucial in disease progression.

AB - BACKGROUND: It is unknown whether disease activity according to consensus criteria (magnetic resonance imaging activity or clinical relapses) associate with cerebrospinal fluid (CSF) changes in progressive multiple sclerosis (MS).OBJECTIVE: To compare CSF biomarkers in active and inactive progressive MS according to consensus criteria.METHODS: Neurofilament light chain (NFL), myelin basic protein (MBP), IgG-index, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), chemokine CXCL13, terminal complement complex, leukocyte counts and nitric oxide metabolites were measured in primary ( n = 26) and secondary progressive MS ( n = 26) and healthy controls ( n = 24).RESULTS: Progressive MS patients had higher CSF cell counts, IgG-index, CHI3L1, MMP-9, CXCL13, NFL and MBP concentrations. Active patients were younger and had higher NFL, CXCL13 and MMP-9 concentrations than inactive patients. Patients with active disease according to consensus criteria or detectable CXCL13 or MMP-9 in CSF were defined as having combined active progressive MS. These patients had increased CSF cell counts, IgG-index and MBP, NFL and CHI3L1 concentrations. Combined inactive patients only had increased IgG-index and MBP concentrations.CONCLUSION: Patients with combined active progressive MS show evidence of inflammation, demyelination and neuronal/axonal damage, whereas the remaining patients mainly show evidence of active demyelination. This challenges the idea that neurodegeneration independent of inflammation is crucial in disease progression.

U2 - 10.1177/1352458517726592

DO - 10.1177/1352458517726592

M3 - Journal article

C2 - 28831853

VL - 23

SP - 1727

EP - 1735

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 13

ER -

ID: 195162929